STRYKER CORP officer Kimberly Ann Montagnino, VP, Chief Communications Officer, had 155 shares of Common Stock withheld on August 1, 2026 to satisfy exercise-price or tax-liability obligations at $325.70 per share, leaving 1,717 shares held directly plus 33 shares held indirectly through a 401(k).
Debra King, VP and Chief Digital and Information Officer of Stryker Corp, had 533 common shares withheld at $325.7000 per share on 2026-08-01 to cover an exercise price or tax liability. After this code F disposition she holds 7036 shares directly and 8 shares indirectly via a 401(k).
Stryker Corp executive Robert S. Fletcher, VP and Chief Legal Officer, reported a disposition of 94 shares of common stock on 2026-08-01 to pay an exercise price or tax liability at $325.70 per share. After this withholding, he holds 10,488 shares directly and 184 shares indirectly through a 401(k). The transaction was not reported under a Rule 10b5-1 trading plan.
Stryker Corp executive M Kathryn Fink, VP and Chief HR Officer, reported an F-code tax- or exercise-related disposition of 111 common shares on August 1, 2026 at $325.70 per share. After this withholding, she directly holds 13,027 shares, including 129 acquired through the Employee Stock Purchase Plan as of June 30, 2026, plus 177 shares held via the 2023 Mary Fink Living Trust and 445 shares held via a 401K.
Stryker Corporation reported strong Q2 2026 results, with net sales of $ 6,589 versus $ 6,022 in 2025 and net earnings of $ 1,276, or $ 3.30 per diluted share. Gross profit margin improved to 68.3% and operating margin to 25.2%, helped by lower import tariffs and reduced inventory step-up amortization.
For the first six months of 2026, net sales were $ 12,609 and net earnings were $ 2,021, or $ 5.23 per diluted share. Adjusted net earnings per diluted share were $ 3.69 in Q2 and $ 6.29 year to date. Operating cash flow increased to $ 1,842, while total debt decreased to $ 14,942 after repaying $ 1,000 of senior notes. Stryker also completed the AVS acquisition for $ 435 in cash plus up to $ 400 in contingent milestone payments, adding a next-generation intravascular lithotripsy platform to its Peripheral Vascular business.
Stryker Corporation reported strong second quarter 2026 results, with net sales of $6.6 billion, up 9.4%, and organic net sales growth of 9.0%. MedSurg and Neurotechnology sales rose 9.7% to $3.625 billion, while Orthopaedics grew 9.1% to $2.964 billion, driven mainly by higher unit volumes.
Reported gross margin was 68.3% and operating margin 25.2%, while adjusted operating income margin increased 170 basis points to 27.4%. Net earnings were $1.276 billion and reported diluted EPS increased 44.1% to $3.30. Adjusted net earnings were $1.424 billion and adjusted diluted EPS rose 17.9% to $3.69. Management stated it "made significant progress in our recovery from the cyber incident" and narrowed full‑year 2026 guidance to organic net sales growth of 8.3%–9.3% and adjusted diluted EPS of $14.95–$15.10, assuming a modestly positive pricing impact and slightly favorable foreign exchange.
Stryker Corporation has recast its prior-period financial statements to align with a new segment structure while highlighting a strong 2025 performance. Net sales grew 11.2% to $25,116 million, with MedSurg and Neurotechnology up 16.5% and Orthopaedics up 5.4%.
Reported net earnings were $3,246 million, or $8.40 diluted EPS, while adjusted net earnings reached $5,267 million and adjusted diluted EPS rose 11.8% to $13.63. The company invested $4,960 million in acquisitions, including the Inari Medical deal, and generated $5,044 million in operating cash flow, supporting dividends and debt repayment.
Stryker Corp President and COO Spencer S. Stiles reported a bona fide gift of 1,607 shares of Common Stock. The shares were donated to a charitable donor advised fund and were transferred at a price of $0.00 per share, meaning there was no sale in the market.
After the gift, Stiles directly holds 76,027 shares of Stryker Common Stock and indirectly holds 1,693 shares through a 401(k) plan. The filing reflects a charitable disposition rather than a trading decision.
STRYKER CORP VP and Chief Legal Officer Robert S. Fletcher sold 4,544 shares of common stock in open-market transactions on May 28, 2026. Sale prices ranged from about $304 to $310 per share, with several trades reported at weighted average prices. The filing notes these sales were made under a Rule 10b5-1 trading plan adopted on February 26, 2026. After the transactions, he holds 10,582 shares directly and 183 shares indirectly through a 401(k) plan.
Stryker Corp director Ronda E. Stryker reported a series of open-market sales of the company’s Common Stock on May 26, 2026 through a Revocable Trust. The filing shows that the trust sold a total of 310,000 shares at weighted average prices ranging from about $310.35 to $315.69 per share. These are indirect transactions attributed to the Revocable Trust associated with the reporting person. Separate holding entries indicate she also has 1,322 shares held directly, 37,600 shares held indirectly through the 1988 William D. Johnston Trust, and 12,177,521 shares held indirectly through the L. Lee Stryker Trust as of the same date, highlighting that the reported sales represent a relatively small portion of her overall indirect ownership.